Business Wire

CA-ANOMALI

1.8.2022 11:02:08 CEST | Business Wire | Press release

Share
Anomali Appoints Cyber Security Expert Steve Benton as Vice President and General Manager to Expand Growth of Anomali Intelligence-Driven Solutions

Anomali , a leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions, today announced that Steve Benton has been appointed to the position of Vice President of Anomali Threat Research (ATR) and General Manager of the Anomali Belfast, Ireland Office. Benton, an experienced cyber security expert has a history of strategic advisory, intelligence sharing and coordinated response across MD, CxO, and board audiences. Benton joins Anomali during a time of rapid global expansion, to deliver guidance to global organizations on investment, strategy and making security a business enabler to rapidly address the evolving global threats of today and in the future.

“Steve brings a wealth of experience to Anomali – both in cybersecurity and in building and contributing to the wider security community. His experience and expertise spanning cyber security advisory, thought leadership, strategic development and execution will be a tremendous asset to our customers, partners, and investors,” said Mark Alba, CPO. “Steve’s extensive experience and expertise has been instrumental in helping guide global organizations on what is required to operate successfully in an ever-increasing and complex threat environment. We are very excited about Steve playing a pivotal role in how Anomali solutions can further help customers to thrive, grow and face security challenges with confidence.”

Benton has more than three decades of experience working with customers to solve their most difficult security challenges. Most recently, Benton was Deputy CISO and latterly CSO for BT where he was accountable for physical and cyber security across investment, posture, and response globally. While at BT, he built and led the Protect BT Services and Operations organization spanning intelligence, offensive security, cyber security operations, physical security operations, strategy, investigations, and incidents. In addition, he innovated proactive threat hunting and wide-ranging intelligence operations to anticipate threats, track threat actors, and their methods. An industry security expert, Benton is a contributing member of the Cyber Defenders Council, Fellow of the Chartered Institute of Information Security and a regular speaker and influencer to the i4 C level community.

“I am excited to join Anomali, the leader of threat-intelligence driven solutions, and contribute to the mission of helping organizations efficiently and effectively stop breaches and advanced adversaries,” said Benton. “As a previous customer, I leveraged the Anomali portfolio at the heart of my drive to improve security posture and disrupt threat actor activities at pace, whilst driving the democratisation of threat intelligence across the business. To know yourself and your adversaries through high fidelity, actionable intelligence, that constantly informs your decisions and guides a dynamic security posture, is the new battleground. And I look forward to bringing my frontline operational and strategic experience to Anomali customers and partners. With cyberattacks on the rise, ever more complex and multidimensional, organizations require an integrated XDR solution to tell them who they are up against, why, when they are being attacked, and how to accelerate their multifaceted response. The Anomali Platform greatly enhances an organization’s ability to address newly detected attacks, cresting threats and subsequent future attacks. Put simply, confidence in the face of uncertainty.”

For more information, visit:
www.anomali.com

Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog

About Anomali

Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management (the “X”) and refined by artificial intelligence, The Anomali Platform, an XDR solution, delivers unique proprietary capabilities that correlate the largest repository of global intelligence with telemetry from customer-deployed security solutions. This combination empowers security operations teams to detect threats with precision, optimize response, achieve resiliency, and ultimately stop attackers and breaches. Our SaaS-based solutions easily integrate into existing security tech stacks through native-cloud, multi-cloud, on-premises, and hybrid deployments. Founded in 2013, Anomali serves global B2B enterprise businesses and large public sector organizations, ISACs, ISAOs, service providers, and Global 1000 customers to help safeguard the world’s critical infrastructure, businesses, and people. Leading venture firms, including Google Ventures, General Catalyst, and IVP, back Anomali.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye